


CLAIMS

1. A combination of :

component A : one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of
5 general formula (A1) :



(A1)

wherein

10

X represents CR⁵R⁶ or NH;

Y¹ represents CR³ or N;

15 Chemical bond between Y²====Y³ represents a single bond or double bond,

with the proviso that when the Y²====Y³ represents a double bond,

Y² and Y³ independently represent CR⁴ or N, and

20

when Y²====Y³ represents a single bond, Y² and Y³ independently represent CR³R⁴ or NR⁴;

Z¹, Z², Z³ and Z⁴ independently represent CH, CR² or N;

25

R¹ represents aryl optionally having 1 to 3 substituents selected from R¹¹, C₃₋₈ cycloalkyl optionally having 1 to 3 substituents selected from R¹¹,

C₁₋₆ alkyl optionally substituted by
 aryl, heteroaryl, C₁₋₆ alkoxyaryl, aryloxy, heteroaryloxy or one or more halogen,
 C₁₋₆ alkoxy optionally substituted by
 carboxy, aryl, heteroaryl, C₁₋₆ alkoxyaryl, aryloxy, heteroaryloxy or one or more
 5 halogen,

or

a 3 to 15 membered mono- or bi-cyclic heterocyclic ring that is saturated or
 unsaturated, and contains 1 to 3 heteroatoms selected from the group
 consisting of N, O and S, and optionally having 1 to 3 substituents selected from

R¹¹

wherein

R¹¹ represents

halogen, nitro, hydroxy, cyano, carboxy, amino, N-(C₁₋₆alkyl)amino, N-
 (hydroxyC₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₁₋₆acyl)amino, N-(formyl)-N-
 15 (C₁₋₆alkyl)amino, N-(C₁₋₆alkanesulfonyl) amino, N-(carboxyC₁₋₆alkyl)-N-(C₁₋₆
 alkyl)amino, N-(C₁₋₆alkoxycarbonyl)amino, N-[N,N-di(C₁₋₆alkyl)amino
 methylene]amino, N-[N,N-di(C₁₋₆alkyl)amino (C₁₋₆ alkyl)methylene]amino, N-
 [N,N-di(C₁₋₆alkyl)amino C₂₋₆alkenyl]amino, aminocarbonyl, N-(C₁₋₆
 6alkyl)aminocarbonyl, N,N-di(C₁₋₆alkyl)aminocarbonyl, C₃₋₈cycloalkyl, C₁₋₆
 20 alkylthio, C₁₋₆alkanesulfonyl, sulfamoyl, C₁₋₆alkoxycarbonyl,

N-arylamino wherein said aryl moiety is optionally having 1 to 3 substituents
 selected from R¹⁰¹, N-(aryl C₁₋₆alkyl)amino wherein said aryl moiety is optionally
 having 1 to 3 substituents selected from R¹⁰¹, aryl C₁₋₆alkoxycarbonyl wherein
 said aryl moiety is optionally having 1 to 3 substituents selected from R¹⁰¹,

25 C₁₋₆alkyl optionally substituted by

mono-, di- or tri- halogen, amino, N-(C₁₋₆alkyl)amino or N,N-di(C₁₋₆alkyl)amino,
 C₁₋₆alkoxy optionally substituted by
 mono-, di- or tri- halogen, N-(C₁₋₆alkyl)sulfonamide, or N-(aryl)sulfonamide,
 or

a 5 to 7 membered saturated or unsaturated ring having 1 to 3 heteroatoms selected from the group consisting of O, S and N, and optionally having 1 to 3 substituents selected from R¹⁰¹

wherein

5 R¹⁰¹ represents

halogen, carboxy, amino, N-(C₁₋₆ alkyl)amino, N,N-di(C₁₋₆alkyl)amino, aminocarbonyl, N-(C₁₋₆alkyl)aminocarbonyl, N,N-di(C₁₋₆alkyl)aminocarbonyl, pyridyl,

C₁₋₆ alkyl optionally substituted by cyano or mono- di- or tri- halogen,

10 or

C₁₋₆alkoxy optionally substituted by cyano, carboxy, amino, N-(C₁₋₆ alkyl)amino, N,N-di(C₁₋₆alkyl)amino, aminocarbonyl, N-(C₁₋₆alkyl)aminocarbonyl, N,N-di(C₁₋₆alkyl)aminocarbonyl or mono-, di- or tri- halogen;

15 R² represents hydroxy, halogen, nitro, cyano, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(hydroxyC₁₋₆alkyl)amino, N-(hydroxyC₁₋₆alkyl)-N-(C₁₋₆alkyl)amino, C₁₋₆ acyloxy, aminoC₁₋₆ acyloxy, C₂₋₆alkenyl, aryl,

a 5-7 membered saturated or unsaturated heterocyclic ring having 1 to 3 heteroatoms selected from the group consisting O, S and N, and optionally substituted by

20

hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, oxo, amino, amino C₁₋₆alkyl, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₁₋₆ acyl)amino, N-(C₁₋₆alkyl)carbonylamino, phenyl, phenyl C₁₋₆ alkyl, carboxy, C₁₋₆alkoxycarbonyl, aminocarbonyl, N-(C₁₋₆alkyl)aminocarbonyl, or N,N-di(C₁₋₆alkyl)amino,

25 -C(O)- R²⁰

wherein

R²⁰ represents C₁₋₆ alkyl, C₁₋₆ alkoxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₁₋₆ acyl)amino, or a 5-7 membered saturated or unsaturated heterocyclic ring having 1 to 3 heteroatoms selected from the group consisting O, S and N, and optionally substituted by

30

C₁₋₆ alkyl, C₁₋₆ alkoxy, oxo, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₁₋₆ acyl)amino, phenyl, or benzyl,

C₁₋₆ alkyl optionally substituted by R²¹

5 or

C₁₋₆ alkoxy optionally substituted by R²¹

wherein

10 R²¹ represents cyano, mono-, di or tri- halogen, hydroxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N- (hydroxyC₁₋₆ alkyl) amino, N-(halophenylC₁₋₆ alkyl) amino, amino C₂₋₆ alkylenyl, C₁₋₆ alkoxy, hydroxyC₁₋₆ alkoxy, -C(O)- R²⁰¹, -NHC(O)- R²⁰¹, C₃₋₈cycloalkyl, isoindolino, phthalimidyl, 2-oxo-1,3-oxazolidinyl, aryl or a 5 or 6 membered saturated or unsaturated heterocyclic ring having 1 to 4 heteroatoms selected from the group consisting O, S and N optionally substituted by

15 hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, hydroxyC₁₋₆ alkoxy, oxo, amino, aminoC₁₋₆alkyl, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₁₋₆ acyl)amino, or benzyl,

wherein

20 R²⁰¹ represents hydroxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N- (halophenylC₁₋₆ alkyl) amino, C₁₋₆alkyl, aminoC₁₋₆ alkyl, aminoC₂₋₆ alkylenyl, C₁₋₆ alkoxy, a 5 or 6 membered saturated or unsaturated heterocyclic ring having 1 to 4 heteroatoms selected from the group consisting O, S and N optionally substituted by

25 hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, hydroxyC₁₋₆ alkoxy, oxo, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₁₋₆ acyl)amino or benzyl;

30 R³ represents hydrogen, halogen, aminocarbonyl, or C₁₋₆ alkyl optionally substituted by aryl C₁₋₆ alkoxy or mono-, di- or tri- halogen;

R⁴ represents hydrogen or C₁₋₆ alkyl;

R⁵ represents hydrogen or C₁₋₆ alkyl; and

5


R⁶ represents halogen, hydrogen or C₁₋₆ alkyl ;

or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ;

optionally in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially ;

10 and

component B : one or more substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]-triazin-4-amine compounds of general formula (B) :



(B),

15

wherein

R¹ is hydrogen, chloro, methyl or methoxy,

R² is hydrogen or methoxy,

with the proviso that at least one of R¹ and R² is other than hydrogen,

20

G¹ represents chloro, (C₁₋₄)-alkyl, (C₁₋₄)-alkoxycarbonyl, 5-membered aza-heteroaryl, or the group -CH₂-OR³, -CH₂-NR⁴R⁵ or -C(=O)-NR⁴R⁶, wherein

R³ is hydrogen, (C₁₋₄)-alkyl, (C₃₋₆)-cycloalkyl or phenyl,

(i) said (C₁₋₄)-alkyl is optionally substituted with hydroxy, (C₁₋₄)-alkoxy, hydroxycarbonyl, (C₁₋₄)-alkoxycarbonyl, amino, aminocarbonyl, mono-(C₁₋₄)-alkylaminocarbonyl, di-(C₁₋₄)-alkylaminocarbonyl, (C₃₋₆)-cycloalkyl or up to three fluoro atoms,

25

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

and

(iii) said phenyl is optionally substituted with one or two substituents independently selected from the group consisting of fluoro, chloro, bromo, cyano, trifluoromethyl, trifluoromethoxy, (C₁-C₄)-alkyl and (C₁-C₄)-alkoxy,

R⁴ is hydrogen or (C₁-C₄)-alkyl,

R⁵ is hydrogen, (C₁-C₄)-alkyl, (C₁-C₄)-alkylcarbonyl, (C₃-C₆)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, (C₁-C₄)-alkoxy, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl, di-(C₁-C₄)-alkylaminocarbonyl or (C₃-C₆)-cycloalkyl,

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

and

(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy, oxo and amino,

R⁶ is hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, (C₁-C₄)-alkoxy, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl, amino, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl, di-(C₁-C₄)-alkylaminocarbonyl or (C₃-C₆)-cycloalkyl,

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

and

(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy, oxo and amino,

or

R⁴ and R⁵, or R⁴ and R⁶, respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 7-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R⁷) and O, and which may be substituted on ring carbon atoms with one or two

substituents independently selected from the group consisting of (C₁-C₄)-alkyl, oxo, hydroxy, amino and aminocarbonyl, and wherein

R⁷ is hydrogen, (C₁-C₄)-alkyl, formyl or (C₁-C₄)-alkylcarbonyl,

5 and
G²

represents chloro, cyano, (C₁-C₄)-alkyl, or the group -CR^{8A}R^{8B}-OH, -CH₂-NR⁹R¹⁰, -C(=O)-NR¹¹R¹² or -CH₂-OR¹⁵, wherein

R^{8A} and R^{8B} are independently selected from the group consisting of hydrogen, (C₁-C₄)-alkyl, cyclopropyl and cyclobutyl,

10 R⁹ is hydrogen or (C₁-C₄)-alkyl,

R¹⁰ is hydrogen, (C₁-C₄)-alkyl, (C₁-C₄)-alkylcarbonyl, (C₃-C₆)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, amino, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl or di-(C₁-C₄)-alkylaminocarbonyl,

15

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

20

and

(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy, oxo and amino,

25

R¹¹ is hydrogen or (C₁-C₄)-alkyl,

R¹² is hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, amino, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl or di-(C₁-C₄)-alkylaminocarbonyl,

30

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

35

and

(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy, oxo and amino,

40

or

R⁹ and R¹⁰, or R¹¹ and R¹², respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 7-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R¹³), O, S and S(O)₂, and which may be substituted on ring

45

carbon atoms with up to three substituents independently selected from the group consisting of fluoro, (C₁-C₄)-alkyl, oxo, hydroxy, amino and aminocarbonyl, and wherein

R¹³ is hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl, formyl or (C₁-C₄)-alkylcarbonyl,


and

R¹⁵ is (C₁-C₄)-alkyl,

with the proviso that G¹ is not chloro when G² is chloro or cyano.

2. The combination according to claim 1, wherein :

said component A is one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A2) :



(A2)

in which :

X represents CR⁵R⁶ or NH;

Y¹ represents CR³ or N;

the chemical bond between Y²—Y³ represents a single bond or double bond, with the proviso that when the Y²—Y³ represents a double bond, Y² and Y³ independently represent CR⁴ or N, and when Y²—Y³ represents a single bond, Y² and Y³ independently represent CR³R⁴ or NR⁴;

Z¹, Z², Z³ and Z⁴ independently represent CH, CR² or N;

R¹ represents aryl optionally having 1 to 3 substituents selected from R¹¹, C₃₋₈ cycloalkyl optionally having 1 to 3 substituents selected from R¹¹,
 5 C₁₋₆ alkyl optionally substituted by aryl, heteroaryl, C₁₋₆ alkoxyaryl, aryloxy, heteroaryloxy or one or more halogen, C₁₋₆ alkoxy optionally substituted by carboxy, aryl, heteroaryl, C₁₋₆ alkoxyaryl, aryloxy, heteroaryloxy or one or more halogen,
 or

10 a 3 to 15 membered mono- or bi-cyclic heterocyclic ring that is saturated or unsaturated, optionally having 1 to 3 substituents selected from R¹¹, and contains 1 to 3 heteroatoms selected from the group consisting of N, O and S,

15 wherein

R¹¹ represents halogen, nitro, hydroxy, cyano, carboxy, amino, N-(C₁₋₆alkyl)amino, N-(hydroxyC₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₁₋₆acyl)amino, N-(formyl)-N-(C₁₋₆alkyl)amino, N-(C₁₋₆alkanesulfonyl) amino, N-(carboxyC₁₋₆alkyl)-N-(C₁₋₆alkyl)amino, N-(C₁₋₆alkoxycarbonyl)amino, N-[N,N-di(C₁₋₆alkyl)amino methylene]amino, N-[N,N-di(C₁₋₆alkyl)amino (C₁₋₆alkyl)methylene]amino, N-[N,N-di(C₁₋₆alkyl)amino C₂₋₆alkenyl]amino, aminocarbonyl, N-(C₁₋₆alkyl)aminocarbonyl, N,N-di(C₁₋₆alkyl)aminocarbonyl, C₃₋₈cycloalkyl, C₁₋₆ alkylthio, C₁₋₆alkanesulfonyl, sulfamoyl, C₁₋₆alkoxycarbonyl,

25 N-arylamino wherein said aryl moiety is optionally having 1 to 3 substituents selected from R¹⁰¹, N-(aryl C₁₋₆alkyl)amino wherein said aryl moiety is optionally having 1 to 3 substituents selected from R¹⁰¹, aryl C₁₋₆alkoxycarbonyl wherein said aryl moiety is optionally having 1 to 3 substituents selected from R¹⁰¹,

30

C₁₋₆alkyl optionally substituted by mono-, di- or tri- halogen, amino, N-(C₁₋₆alkyl)amino or N,N-di(C₁₋₆alkyl)amino,

C₁₋₆alkoxy optionally substituted by mono-, di- or tri- halogen, N-(C₁₋₆alkyl)sulfonamide, or N-(aryl)sulfonamide,

or

a 5 to 7 membered saturated or unsaturated ring having 1 to 3 heteroatoms selected from the group consisting of O, S and N, and optionally having 1 to 3 substituents selected from R¹⁰¹

wherein

R¹⁰¹ represents halogen, carboxy, amino, N-(C₁₋₆ alkyl)amino, N,N-di(C₁₋₆alkyl)amino, aminocarbonyl, N-(C₁₋₆alkyl)aminocarbonyl, N,N-di(C₁₋₆alkyl)aminocarbonyl, pyridyl,

C₁₋₆ alkyl optionally substituted by cyano or mono- di- or tri-halogen,

and

C₁₋₆alkoxy optionally substituted by cyano, carboxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, aminocarbonyl, N-(C₁₋₆alkyl)aminocarbonyl, N,N-di(C₁₋₆alkyl)aminocarbonyl or mono-, di- or tri- halogen;

R² represents hydroxy, halogen, nitro, cyano, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(hydroxyC₁₋₆alkyl)amino, N-(hydroxyC₁₋₆alkyl)-N-(C₁₋₆alkyl)amino, C₁₋₆ acyloxy, aminoC₁₋₆ acyloxy, C₂₋₆alkenyl, aryl,

a 5-7 membered saturated or unsaturated heterocyclic ring having 1 to 3 heteroatoms selected from the group consisting O, S and N, and optionally substituted by

hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, oxo, amino, amino C₁₋₆alkyl, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₁₋₆ acyl)amino, N-(C₁₋₆alkyl)carbonylamino, phenyl, phenyl C₁₋₆ alkyl, carboxy, C₁₋₆alkoxycarbonyl, aminocarbonyl, N-(C₁₋₆alkyl)aminocarbonyl, or N,N-di(C₁₋₆alkyl)amino, -C(O)- R²⁰

wherein

R²⁰ represents C₁₋₆ alkyl, C₁₋₆ alkoxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₁₋₆ acyl)amino, or a 5-7 membered saturated or unsaturated heterocyclic ring having 1 to 3 heteroatoms selected from the group consisting O, S and N, and optionally substituted by C₁₋₆ alkyl, C₁₋₆ alkoxy, oxo, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₁₋₆ acyl)amino, phenyl, or , benzyl,

C₁₋₆ alkyl optionally substituted by R²¹,

or

C₁₋₆ alkoxy optionally substituted by R²¹,

wherein

R²¹ represents cyano, mono-, di or tri- halogen, hydroxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(hydroxyC₁₋₆ alkyl) amino, N-(halophenylC₁₋₆ alkyl) amino, amino C₂₋₆ alkylenyl, C₁₋₆ alkoxy, hydroxyC₁₋₆ alkoxy, -C(O)-R²⁰¹, -NHC(O)- R²⁰¹, C₃₋₈cycloalkyl, isoindolino, phthalimidyl, 2-oxo-1,3-oxazolidinyl, aryl or a 5 or 6 membered saturated or unsaturated heterocyclic ring having 1 to 4 heteroatoms selected from the group consisting O, S and N , and optionally substituted by hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl,

hydroxyC₁₋₆ alkoxy, oxo, amino, aminoC₁₋₆alkyl, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₁₋₆ acyl)amino, or benzyl,

5 wherein

R²⁰¹ represents hydroxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N- (halophenylC₁₋₆ alkyl) amino, C₁₋₆alkyl, aminoC₁₋₆ alkyl, aminoC₂₋₆ alkylenyl, C₁₋₆ alkoxy, a 5 or 6 membered saturated or unsaturated heterocyclic ring having 1 to 4 heteroatoms selected from the group consisting O, S and N, and optionally substituted by hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy carbonyl, hydroxyC₁₋₆ alkoxy, oxo, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₁₋₆ acyl)amino or benzyl;

R³ represents hydrogen, halogen, aminocarbonyl, or C₁₋₆ alkyl optionally substituted by aryl C₁₋₆ alkoxy or mono-, di- or tri- halogen;

R⁴ represents hydrogen or C₁₋₆ alkyl;

R⁵ represents hydrogen or C₁₋₆ alkyl; and

R⁶ represents halogen, hydrogen or C₁₋₆ alkyl ;

or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ;

optionally in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.

3. The combination according to claim 1, wherein :

said component A is one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) according to claim 1, which is selected from the list consisting of
 5 specific compound Examples 1-1 to 1-210 on pp. 47 to 106, specific compound Examples 2-1 to 2-368 on pp. 107 to 204, specific compound Examples 3-1 to 3-2 on pp. 205 to 207, and specific compound Examples 4-1 to 4-2 on pp. 208 to 210, of in International patent application PCT/EP2003/010377, published as WO 04/029055 A1 on April 08, 2004 ;

10 or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ;
 optionally in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.

4. The combination according to claim 2, wherein :

15 said component A is one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A2) according to claim 2, which is selected from the list consisting of :

Example 1 : N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide

Example 2 : N-(8-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propoxy}-7-methoxy-
 20 2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide

Example 3 : N-(8-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propoxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2,4-dimethyl-1,3-thiazole-5-carboxamide

Example 4 : 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]-1,3-thiazole-5-carboxamide.

25 Example 5 : 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]isonicotinamide

Example 6 : 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]-4-methyl-1,3-thiazole-5-carboxamide

Example 7 : 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-
 30 dihydroimidazo[1,2-c]quinazolin-5-yl]-4-propylpyrimidine-5-carboxamide

Example 8 : N-{8-[2-(4-ethylmorpholin-2-yl)ethoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}nicotinamide

Example 9 : N-{8-[2-(dimethylamino)ethoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide

5 Example 10 : N-(8-{3-[2-(hydroxymethyl)morpholin-4-yl]propoxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide



Example 11 : N-(8-{3-[2-(hydroxymethyl)morpholin-4-yl]propoxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide

10 Example 12 : N-{8-[3-(dimethylamino)propoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}nicotinamide 1-oxide








Example 13 : 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide.








Example 14 : N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]-6-(2-pyrrolidin-1-ylethyl)nicotinamide.







15 Example 15 : 6-(cyclopentylamino)-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide

Example	Structure
16	
17	







18	 <chem>COc1ccc(cc1N2C=NC3C=NC(=N2)C3)OCCCCOCCO</chem>
19	 <chem>COc1ccc(cc1N2C=NC3C=NC(=N2)C3)OCCCCOCCN1CCCC1</chem>
20	 <chem>COc1ccc(cc1N2C=NC3C=NC(=N2)C3)OCCCCOCOC</chem>
21	 <chem>COc1ccc(cc1N2C=NC3C=NC(=N2)C3)OCCCCOCCNCC</chem>
22	 <chem>COc1ccc(cc1N2C=NC3C=NC(=N2)C3)OCCCCOCOC</chem>
23	 <chem>COc1ccc(cc1N2C=NC3C=NC(=N2)C3)OCCCCOCN(C)C</chem>







24	 <chem>COc1ccc(cc1N2C=NC(NC(=O)c3ccncc3)C2)c3ccc(OCCCCN4CCOCC4)cc3</chem>
25	 <chem>NC1=CC=CC=C1C(=O)Nc2nc3cc(NC(=O)c4ccncc4)nn3c2c5ccc(OCCCCN6CCOCC6)cc5</chem>
26	 <chem>CN1C=CC=C1C(=O)Nc2nc3cc(NC(=O)c4ccncc4)nn3c2c5ccc(OCCCCN6CCOCC6)cc5</chem>
27	 <chem>COc1ccc(cc1N2C=NC(NC(=O)c3ccncc3)C2)c4ccc(OCCCCN5CCOCC5C)cc4</chem>
28	 <chem>COc1ccc(cc1N2C=NC(NC(=O)c3cc(C)ccn3)C2)c4ccc(OCCCCN5CCOCC5C)cc4</chem>
29	 <chem>CC(=O)Nc1ccc(NC(=O)Nc2nc3cc(NC(=O)c4ccncc4)nn3c2c5ccc(OCCCCN6CCOCC6C)cc5)cc1</chem>
30	 <chem>COc1ccc(cc1N2C=NC(NC(=O)c3cc(C)nn3)C2)c4ccc(OCCCCN5CCOCC5)cc4</chem>








31	 <chem>CN1C=CC(=C(C=C1)C(=O)Nc2nc3c(ncn3)cc2C)c4cc(OC)c(OCCN5CCOCC5)cc4</chem>
32	 <chem>CN1C=CC(=C(C=C1)C(=O)Nc2nc3c(ncn3)cc2C)c4cc(OC)c(OCCN5CCOCC5)cc4</chem>
33	 <chem>CN1C=CC(=C(C=C1)C(=O)Nc2nc3c(ncn3)cc2C)c4cc(OC)c(OCCN5CCOCC5)cc4</chem>
34	 <chem>Nc1cc2c(ncn2)cc1C(=O)Nc3nc4c(ncn4)cc3c5cc(OC)c(OCCN6CCOCC6)cc5</chem>
35	 <chem>c1ccc(C(=O)Nc2nc3c(ncn3)cc2c4ccncc4)cc1c5cc(OC)c(OCCN6CCOCC6)cc5</chem>
36	 <chem>CN(C)CCOC1=CC=C(C=C1OC)c2cc3c(ncn3)cc2C(=O)Nc4cc(C)nc(NCCN(C)C)c4</chem>
37	 <chem>Nc1cc2c(ncn2)cc1C(=O)Nc3nc4c(ncn4)cc3c5cc(OC)c(OCCN6CCOCC6)cc5</chem>








38	 <chem>CN1=NC=C(C(=O)Nc2nc3c(ncn3C)ccc2OC(=O)OCCN(C)C(C)C)C=C1</chem>
39	 <chem>CN1=NC=C(C(=O)Nc2nc3c(ncn3C)ccc2OC(=O)OCCN(C)C(C)C)C=C1</chem>
40	 <chem>CCOCCNc1nc2c(ncn2C)ccc1C(=O)Nc3cc(OC)c(OCCN(C)C(C)C)cc3</chem>
41	 <chem>COCOCNc1nc2c(ncn2C)ccc1C(=O)Nc3cc(OC)c(OCCN(C)C(C)C)cc3</chem>
42	 <chem>CN(C)CCOC(=O)c1cc(OC)c(OCCN(C)C(C)C)cc1Nc2nc3c(ncn3C)ccc2</chem>
43	 <chem>C1CCN(C1)CCCNc2nc3c(ncn3C)ccc2C(=O)Nc4cc(OC)c(OCCN(C)C(C)C)cc4</chem>








44	<chem>COCN1C=NC(=C1)C(=O)Nc2nc3c(ncn3C)cc(OC)c2OCCN4CCOCC4</chem>
45	<chem>CN(C)CCNc1nc2c(ncn2)cc(OC)c1C(=O)Nc3nc4c(ncn4)cc(OC)c3OCCN5CCOCC5</chem>
46	<chem>CN(C)CCOCc1cc(OC)c2c(c1)nc3c(ncn3)cc(OC)c2C(=O)Nc4cc(N)ccn4</chem>
47	<chem>C1CCN(C1)c2nc3c(ncn3)cc(OC)c2C(=O)Nc4nc5c(ncn5)cc(OC)c4OCCN6CCOCC6</chem>
48	<chem>CN1CCN(C1)c2nc3c(ncn3)cc(OC)c2C(=O)Nc4nc5c(ncn5)cc(OC)c4OCCN6CCOCC6</chem>
49	<chem>C1CCN(C1)c2nc3c(ncn3)cc(OC)c2C(=O)Nc4nc5c(ncn5)cc(OC)c4OCCN6CCOCC6</chem>








50	 HCl
51	 HCl
52	 HCl
53	
54	
55	








56	
57	
58	
59	
60	
61	








62	 <chem>COc1cc(OC(=O)Nc2nc3c(ncn3C)ccc2C4=CC=CC=C4C(F)(F)F)ccc1OCCN5CCOCC5</chem>
63	 <chem>CC(C)C(=O)Nc1ccc(C(=O)Nc2nc3c(ncn3C)ccc2C4=CC=CC=C4C(OC)C5=CC(OC)C=C5OCCN6CCOCC6)cc1</chem>
64	 <chem>COc1cc(OC(=O)Nc2nc3c(ncn3C)ccc2C4=CC=CC=C4C5=CC=CC=C5C(=O)N6CCN(C)CC6)ccc1OCCN7CCOCC7</chem>
65	 <chem>COc1cc(OC(=O)Nc2nc3c(ncn3C)ccc2C4=CC=CC=C4C5=CC=CC=C5C(=O)N6CCN(C)CC6)ccc1OCCN7CCOCC7</chem>
66	 <chem>COc1cc(OC(=O)Nc2nc3c(ncn3C)ccc2C4=CC=CC=C4C5=CC=CC=C5C(=O)N6CCN(C)CC6)ccc1OCCN7CCOCC7</chem>
67	 <chem>COc1cc(OC(=O)Nc2nc3c(ncn3C)ccc2C4=CC=CC=C4C5=CC=CC=C5C(=O)N6CCN(C)CC6)ccc1OCCN7CCOCC7</chem>
68	 <chem>COc1cc(OC(=O)Nc2nc3c(ncn3C)ccc2C4=CC=CC=C4C5=CC=CC=C5C(=O)N6CCN(C)CC6)ccc1OCCN7CCOCC7</chem>

69	 <chem>CN(C)CCOC1=CC=C2C(=C1)N=CN=C2C(=N3C=NC(=S3)C)NC(=O)C4=CC=C(C)N=C4</chem>
70	 <chem>CN(C)CCOC1=CC=C2C(=C1)N=CN=C2C(=N3C=CC=C(C)N3)NC(=O)C4=CC=CC=C4</chem>
71	 <chem>CC(C)NC(=O)Nc1ccc(cc1)C(=O)Nc2nc3c(ncn3C)nc2C(=O)C4=CC=C(OC)C(=C4)OCCN5CCOCC5</chem>
72	 <chem>C1CCN1c2ccc(cc2)C(=O)Nc3nc4c(ncn4)nc3C(=O)C5=CC=C(OC)C(=C5)OCCN6CCOCC6</chem>
73	 <chem>CN(C)c1ccc(cc1)C(=O)Nc2nc3c(ncn3)nc2C(=O)C4=CC=C(OC)C(=C4)OCCN5CCOCC5</chem>
74	 <chem>c1ccc(cc1)C(=O)Nc2nc3c(ncn3)nc2C(=O)C4=CC=C(OC)C(=C4)OCCN5CCOCC5</chem>
75	 <chem>c1ccc(cc1)C(=O)Nc2nc3c(ncn3)nc2C(=O)C4=CC=C(OC)C(=C4)OCCN5CCCC5</chem>

76	 <chem>COc1cc(OC(=O)Nc2nc3ccncc3n2)cc(OC4CCNCC4)c1</chem>
77	 <chem>CCNC(=O)Nc1ccc(C(=O)Nc2nc3ccncc3n2)cc1</chem> <chem>COc1cc(OC(=O)Nc2nc3ccncc3n2)cc(OC4CCNCC4)c1</chem>
78	 <chem>Fc1ccc(C(=O)Nc2nc3ccncc3n2)cc1</chem> <chem>COc1cc(OC(=O)Nc2nc3ccncc3n2)cc(OC4CCNCC4)c1</chem>
79	 <chem>Nc1ccoc(C(=O)Nc2nc3ccncc3n2)c1</chem> <chem>COc1cc(OC(=O)Nc2nc3ccncc3n2)cc(OC4CCNCC4)c1</chem>
80	 <chem>CCNC(=O)Nc1cc(C(=O)Nc2nc3ccncc3n2)cs1</chem> <chem>COc1cc(OC(=O)Nc2nc3ccncc3n2)cc(OC4CCNCC4)c1</chem>
81	 <chem>c1ccncc(C(=O)Nc2nc3ccncc3n2)c1</chem> <chem>COc1cc(OC(=O)Nc2nc3ccncc3n2)cc(OC4CCNCC4)c1</chem>
82	 <chem>COc1cc(OC(=O)Nc2nc3ccncc3n2)cc(OC4CCNCC4)c1</chem> <chem>NCCOC1=CC=C(C=C1)C(=O)Nc2nc3ccncc3n2</chem>

83	 <chem>COc1cc(ccc1N2C=NC3C=NC=N3N2C(=O)c4ccc(N)cn4)OCCCN5CCOCC5</chem>
84	 <chem>COc1cc(ccc1N2C=NC3C=NC=N3N2C(=O)c4ccncc4)OCCCN5CCOCC5</chem>
85	 <chem>COc1cc(ccc1N2C=NC3C=NC=N3N2C(=O)c4ccncc4)OCCCN(C)C</chem>
86	 <chem>COc1cc(ccc1N2C=NC3C=NC=N3N2C(=O)c4ccncc4)OCCCN(C)C(C)C</chem>
87	 <chem>COc1cc(ccc1N2C=NC3C=NC=N3N2C(=O)c4ccncc4)OCCN(C)C</chem>
88	 <chem>COc1cc(ccc1N2C=NC3C=NC=N3N2C(=O)c4ccncc4)OCCN(C)C</chem>
89	 <chem>COc1cc(ccc1N2C=NC3C=NC=N3N2C(=O)c4ccncc4)OCCN(C)C</chem>

90	 <chem>CN(C)c1cc(C(=O)Nc2nc3c(cc2)nc4c3cc(OC)c(OCCCN5CCOCC5)c4)ccn1</chem>
91	 <chem>CSc1cc(C(=O)Nc2nc3c(cc2)nc4c3cc(OC)c(OCCCN5CCOCC5)c4)ccn1</chem>
92	 <chem>OC(=O)C(F)(F)F</chem> <chem>c1ccc(C(=O)Nc2nc3c(cc2)nc4c3cc(OC)c(OCCCN5CCOCC5)c4)ccn1</chem>
93	 <chem>c1ccc(C(=O)Nc2nc3c(cc2)nc4c3cc(OC)c(OCCCN5CCOCC5)c4)cc1</chem>
94	 <chem>Cc1nc(C)sc1C(=O)Nc2nc3c(cc2)nc4c3cc(OC)c(OCCCN5CCOCC5)c4</chem>
95	 <chem>COC(=O)c1cc(C(=O)Nc2nc3c(cc2)nc4c3cc(OC)c(OCCCN5CCOCC5)c4)ccn1</chem>
96	 <chem>c1cc(C(=O)Nc2nc3c(cc2)nc4c3cc(OC)c(OCCCN5CCOCC5)c4)oc1</chem>

97	
98	
99	
100	
101	
102	
103	

or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ;

optionally in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.

4. The combination according to any one of claims 1 to 3, wherein :

5

said component B is one or more substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]-triazin-4-amine compounds of general formula (B) according to claim 1, which is selected from the list consisting of :

Example 1

10 4-{{4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}piperazin-2-one

Example 2

4-{{4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}piperazin-2-one dihydrochloride

15

Example 3

(3*R*)-3-({[4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}amino)pyrrolidin-2-one dihydrochloride

Example 4

20 (3*R*)-3-({[4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}amino)pyrrolidin-2-one

Example 5

4-{{4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}piperazin-2-one

25

Example 6

4-{{4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}piperazin-2-one dihydrochloride

Example 7

30 (3*R*)-3-({[4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}amino)pyrrolidin-2-one dihydrochloride

Example 8

(3*R*)-3-({[4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}amino)pyrrolidin-2-one

Example 9

35 *N*²-{{4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}glycinamide dihydrochloride

Example 10

6-(Ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(morpholin-4-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine

Example 11

5 1-(4-{{4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl}methyl}piperazin-1-yl)ethanone dihydrochloride

Example 12

[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methanol bis(formiate)

10 Example 13

4-{{4-Amino-6-(hydroxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl}methyl}piperazin-2-one

Example 14

15 7-{{[(3S)-3-Amino-3-methylpyrrolidin-1-yl]methyl}-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

Example 15

7-{{[(3S)-3-Amino-3-methylpyrrolidin-1-yl]methyl}-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine

Example 16

20 1-(4-{{4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl}methyl}piperazin-1-yl)ethanone dihydrochloride

Example 17

6-(Methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine formiate

25 Example 18

6-(Ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine

Example 19

6-(Ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine dihydrochloride

30 Example 20

1-(4-{{4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl}methyl}piperazin-1-yl)ethanone

Example 21

35 4-{{4-Amino-6-[(2-hydroxyethoxy)methyl]-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl}methyl}piperazin-2-one formiate

Example 22

2-{{4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}methoxy}ethanol dihydrochloride

Example 23

6-(Butoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine formiate

Example 24

5 5-(7-Methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)-6-(propoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine bis(formiate)

Example 25

6-[(Cyclopropylmethoxy)methyl]-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine bis(formiate)

10 Example 26

6-[(Cyclobutyloxy)methyl]-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine

Example 27

15 6-(Isopropoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine formiate

Example 28

6-[(2-Methoxyethoxy)methyl]-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine formiate

Example 29

20 5-(7-Methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)-6-[(2,2,2-trifluoroethoxy)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-amine formiate

Example 30

6-[(2-Aminoethoxy)methyl]-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

25 Example 31

Methyl {[4-amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methoxy}acetate

Example 32

30 {[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methoxy}acetic acid

Example 33

2-[[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methoxy}acetamide

Example 34

35 2-({7-[(4-Acetylpiperazin-1-yl)methyl]-4-amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}methoxy)acetamide

Example 35

5-(7-Methoxy-5-methyl-1-benzothiophen-2-yl)-6-(phenoxymethyl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine bis(formiate)

Example 36

5-(7-Methoxy-5-methyl-1-benzothiophen-2-yl)-6-[(methylamino)methyl]-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

Example 37

5 6-[(Dimethylamino)methyl]-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

Example 38

6-[(Ethylamino)methyl]-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

10 Example 39

2-({[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}amino)ethanol trihydrochloride

Example 40

15 *rac*-1-({[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}piperidin-3-ol trihydrochloride

Example 41

1-({[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}piperidin-4-ol trihydrochloride

Example 42

20 *rac*-1-({[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}pyrrolidin-3-ol trihydrochloride

Example 43

6-[(Diethylamino)methyl]-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

25 Example 44

6-[(Cyclobutylamino)methyl]-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

Example 45

30 5-(7-Methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)-6-(pyrrolidin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

Example 46

6-[(Cyclopropylamino)methyl]-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

Example 47

35 6-({[(Cyclopropylmethyl)amino]methyl}-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

Example 48

N-({[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}glycine trihydrochloride

Example 49

4-{{4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)methyl}piperazin-2-one trihydrochloride

Example 50

5 [4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(morpholin-4-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)methanol

Example 51

(3S)-3-({[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(morpholin-4-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)methyl}amino)pyrrolidin-2-one

10

Example 52

4-{{4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(morpholin-4-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)methyl}piperazin-2-one

Example 53

15 *rac*-1-({[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(morpholin-4-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)methyl}amino)propan-2-ol

Example 54

1-({[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(morpholin-4-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)methyl}amino)-2-methylpropan-2-ol

20

Example 55

1-(4-{{4-Amino-6-(hydroxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}piperazin-1-yl)ethanone

Example 56

(3R)-3-({[7-[(4-Acetylpiperazin-1-yl)methyl]-4-amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)methyl}amino)pyrrolidin-2-one

25

Example 57

1-(4-{{4-Amino-6-({(2-hydroxy-2-methylpropyl)amino)methyl}-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}piperazin-1-yl)ethanone

Example 58

30 4-({4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-6-[(3-oxopiperazin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}piperazine-1-carbaldehyde formiate

Example 59

4-({7-[(4-Acetylpiperazin-1-yl)methyl]-4-amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)methyl}piperazin-2-one

35

Example 60

Methyl 4-amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylcarbonyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylate bis(formiate)

Example 61

5-(7-Methoxy-5-methyl-1-benzothiophen-2-yl)-6-(1,3-oxazol-5-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

Example 62

5 6-(Aminomethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

Example 63

N-{[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}acetamide bis(trifluoroacetate)

10 Example 64

N-{[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}acetamide dihydrochloride

Example 65

15 *N*-{[4-Amino-7-[(4-formylpiperazin-1-yl)methyl]-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}acetamide formiate

Example 66

N-{[7-[(4-Acetyl)piperazin-1-yl)methyl]-4-amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}acetamide

Example 67

20 *N*-{[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-[(3-oxopiperazin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}acetamide

Example 68

4-Amino-6-(hydroxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazine-7-carbonitrile

25 Example 69

4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazine-7-carbonitrile

Example 70

30 4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazine-7-carbonitrile

Example 71

4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-6-[(3-oxopiperazin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazine-7-carbonitrile

Example 72

35 *N,N'*-{[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazine-6,7-diyl]bis(methylene)}diacetamide

Example 73

2-[4-Amino-6-(hydroxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]propan-2-ol

Example 74

4-{{[4-Amino-7-(2-hydroxypropan-2-yl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}piperazin-2-one

Example 75

5 [4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]methanol

Example 76

4-{{[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}piperazin-2-one

10 Example 77

1-({[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}amino)-2-methylpropan-2-ol formiate

Example 78

15 1-({[4-Amino-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}amino)-2-methylpropan-2-ol

Example 79

[4-Amino-7-chloro-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methanol

Example 80

20 4-{{[4-Amino-7-chloro-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}piperazin-2-one

Example 81

1-({[4-Amino-7-chloro-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}amino)-2-methylpropan-2-ol formiate

25 Example 82

1-({[4-Amino-7-chloro-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]methyl}amino)-2-methylpropan-2-ol

Example 83

30 7-Chloro-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine

Example 84

5-(7-Methoxy-5-methyl-1-benzothiophen-2-yl)-6-methyl-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine formiate

Example 85

35 6-Chloro-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-7-(piperazin-1-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine trihydrochloride

Example 86

[4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methanol

Example 87

1-{{4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}imidazolidin-2-one

Example 88

5 4-{{4-Amino-5-(7-methoxy-1-benzothiophen-2-yl)-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}piperazin-2-one

Example 89

4-{{4-Amino-6-(methoxymethyl)-5-(5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}piperazin-2-one

10 Example 90

1-[4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]ethanol

Example 91

15 [4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl](cyclopropyl)methanol

Example 92





(3S)-3-({[4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}amino)pyrrolidin-2-one





Example 93

20 (3S)-3-({[4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}amino)pyrrolidin-2-one

25

Example No.	Structure
94	

Example No.	Structure
95	 <p>Chemical structure of Example 95: A triazole-fused benzimidazole core substituted with a 4-methoxy-3-methylphenyl group, a 2-ethoxyethyl group, and a 1-(2,2-dimethyl-1-oxoethyl)pyrrolidine group.</p>
96	 <p>Chemical structure of Example 96: A triazole-fused benzimidazole core substituted with a 4-methoxy-3-methylphenyl group, a 2-ethoxyethyl group, and a pyrrolidine group.</p>
97	 <p>Chemical structure of Example 97: A triazole-fused benzimidazole core substituted with a 4-methoxy-3-methylphenyl group, a 2-ethoxyethyl group, and a 3-hydroxyazetidine group.</p>
98	 <p>Chemical structure of Example 98: A triazole-fused benzimidazole core substituted with a 4-methoxy-3-methylphenyl group, a 2-ethoxyethyl group, and a 4-hydroxypiperidine group.</p>

Example No.	Structure
99	 <p>Chemical structure of Example 99: A triazolo[4,5-b]pyridine core substituted with an amino group (NH₂) at position 4, a 2-ethoxy-5-(4-methoxy-3-methylphenyl)thien-3-yl group at position 5, and a (1,3-dioxolane-5-yl)methyl group at position 6. The triazole ring is further substituted with a 1,3-dioxolane-5-ylmethyl group.</p>
100	 <p>Chemical structure of Example 100: A triazolo[4,5-b]pyridine core substituted with an amino group (NH₂) at position 4, a 2-ethoxy-5-(4-methoxy-3-methylphenyl)thien-3-yl group at position 5, and a (1,3-dioxolane-5-yl)methyl group at position 6. The triazole ring is further substituted with a 1,3-dioxolane-5-ylmethyl group.</p>
101	 <p>Chemical structure of Example 101: A triazolo[4,5-b]pyridine core substituted with an amino group (NH₂) at position 4, a 2-ethoxy-5-(4-methoxy-3-methylphenyl)thien-3-yl group at position 5, and a (1,3-dioxolane-5-yl)methyl group at position 6. The triazole ring is further substituted with a 1,3-dioxolane-5-ylmethyl group.</p>
102	 <p>Chemical structure of Example 102: A triazolo[4,5-b]pyridine core substituted with an amino group (NH₂) at position 4, a 2-ethoxy-5-(4-methoxy-3-methylphenyl)thien-3-yl group at position 5, and a (1,3-dioxolane-5-yl)methyl group at position 6. The triazole ring is further substituted with a 1,3-dioxolane-5-ylmethyl group.</p>

Example No.	Structure
103	
104	
105	

Example 106

4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-N-[(3R)-2-oxopyrrolidin-3-yl]pyrrolo[2,1-f][1,2,4]triazine-7-carboxamide





5





Example 107

4-{[4-Amino-6-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]carbonyl}piperazin-2-one

Example No.	Structure
-------------	-----------

Example No.	Structure
108	 <chem>CC1=CC=C(C=C1SC2C=CC3=C2N=CN3C4=NC=NC(=N4)N)COC5=CC=C(C=C5)OC</chem>
109	 <chem>CC1=CC=C(C=C1SC2C=CC3=C2N=CN3C4=NC=NC(=N4)N)COC5=CC=C(C=C5)OC</chem>
110	 <chem>CC1=CC=C(C=C1SC2C=CC3=C2N=CN3C4=NC=NC(=N4)N)COC5=CC=C(C=C5)OC</chem>
111	 <chem>CC1=CC=C(C=C1SC2C=CC3=C2N=CN3C4=NC=NC(=N4)N)COC5=CC=C(C=C5)OC</chem>

Example No.	Structure
112	 <chem>Cc1cc(OC)c(SC2=C(C3=CC=CC=C3N2)C4=NC5=NC=NC=C5N4C(=O)N6CCOCC6)cc1OCC</chem>
113	 <chem>NC(=O)N1CCCC1C(=O)N2C(=C3C4=NC5=NC=CC=C5N4C(=O)N2C3)C6=CC=CC=C6C6=CC(OC)=C(C)SC6OCC</chem>
114	 <chem>CN(C)C(=O)N2C(=C3C4=NC5=NC=CC=C5N4C(=O)N2C3)C6=CC=CC=C6C6=CC(OC)=C(C)SC6OCC</chem>
115	 <chem>C1CC1C(=O)N2C(=C3C4=NC5=NC=CC=C5N4C(=O)N2C3)C6=CC=CC=C6C6=CC(OC)=C(C)SC6OCC</chem>

Example No.	Structure
116	 <chem>COc1cc(C)c2c(s1)C(C2)C(=O)N[C@@H]3CCNC3C4=CN=C(N)N=C4COC5=CC=CC=C5C</chem>
117	 <chem>COc1cc(C)c2c(s1)C(C2)C(=O)N[C@@H]3CCNC3C4=CN=C(N)N=C4COC5=CC=CC=C5C</chem>
118	 <chem>COc1cc(C)c2c(s1)C(C2)C(=O)N[C@@H]3CCNC3C4=CN=C(N)N=C4COC5=CC=CC=C5C</chem>
119	 <chem>COc1cc(C)c2c(s1)C(C2)C(=O)N[C@@H]3CCNC3C4=CN=C(N)N=C4COC5=CC=CC=C5C</chem>

Example No.	Structure
120	 <chem>COc1cc(C)cc(S1C2=CN3C(=N1)N=CN=C3N2C(=O)N4CC(O)CC4)cc1</chem>
121	 <chem>COc1cc(C)cc(S1C2=CN3C(=N1)N=CN=C3N2C(=O)N4CC(O)CC4)cc1</chem>
122	 <chem>COc1cc(C)cc(S1C2=CN3C(=N1)N=CN=C3N2C(=O)N4C(F)(F)CC4)cc1</chem>
123	 <chem>COc1cc(C)cc(S1C2=CN3C(=N1)N=CN=C3N2C(=O)N4CC(=O)S4)cc1</chem>

Example 124

4-{{4-Amino-5-(5,7-dimethoxy-1-benzothiophen-2-yl)-6-(methoxymethyl)pyrrolo[2,1-f]-[1,2,4]triazin-7-yl)methyl}piperazin-2-one

Example 125

5 4-{{4-Amino-7-(hydroxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)methyl}piperazin-2-one

Example 126

4-{{4-Amino-7-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)methyl}piperazin-2-one

10 Example 127

4-{{4-Amino-7-(ethoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)methyl}piperazin-2-one

or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ;

15 optionally in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.

5. The combination according to any one of claims 1 to 4, wherein said component A is 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide.

20

6. The combination according to any one of claims 1 to 4, wherein said component A is 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride.

25

7. The combination according to any one of claims 1 to 6, wherein said component B is 4-{{4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}piperazin-2-one.

30 8. The combination according to any one of claims 1 to 7, wherein said component A is 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide and said component B is

4-{{4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f]-[1,2,4]triazin-7-yl)methyl}piperazin-2-one.

9. The combination according to any one of claims 1 to 7, wherein said component A is 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride and said component B is 4-{{4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f]-[1,2,4]triazin-7-yl)methyl}piperazin-2-one.

10. Use of a combination according to any one of claims 1 to 9 for the preparation of a medicament for the treatment or prophylaxis of a cancer, particularly endometrial cancer (hereinafter abbreviated to "EC"), particularly 1st line, 2nd line, relapsed, refractory, type I or type II EC, or endometriosis.

11. Use according to claim 10, wherein said cancer is endometrial cancer (hereinafter abbreviated to "EC").

12. Use according to claim 10 or 11, wherein said cancer is 1st line, 2nd line, relapsed, refractory, type I EC.

13. Use according to claim 10 or 11, wherein said cancer is 1st line, 2nd line, relapsed, refractory, type II EC, or endometriosis.

14. A kit comprising a combination of :

component A : one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof, according to any one of claims 1 to 9 ;

component B : one or more substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]-triazin-4-amine compounds of general formula (B), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof, according to any one of claims 1 to 9 ;

in which optionally both or either of said components A) and B) are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.

15. The kit according to claim 14, wherein said component A is 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide and said component B is 4-[[4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl]piperazin-2-one.

16. The kit according to claim 14, wherein said component A is 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride and said component B is 4-[[4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl]piperazin-2-one.

17. Use of a biomarker such as the loss of tumor suppressor PTEN or FBXW7,

either alone or in combination with another form of PI3K pathway activation selected from perturbation of any of the following alone or in combination : mutation in PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 and/or FGFR4; PTEN loss and alteration of PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 and/or FGFR4, which may be measured at either the protein level, mRNA level, or DNA level,

for predicting the sensitivity and/or resistance of a patient with endometrial cancer (hereinafter abbreviated to "EC"), particularly 1st line, 2nd line, relapsed, refractory, type I or type II EC, or endometriosis, to a combination of a component A and a component B of any one of claims 1 to 9, thus providing rationale-based dosage as defined herein to overcome said resistance of a patient with endometrial cancer (hereinafter abbreviated to "EC"), particularly 1st line, 2nd

line, relapsed, refractory, type I or type II EC, or endometriosis, to a combination of a component A and a component B of any one of claims 1 to 9 (patient selection or stratification).

18. A method of determining the loss of tumor suppressor PTEN or FBXW7.

19. A method for determining perturbations in PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, , PIK3R5, FGFR1, FGFR2, FGFR3 and/or FGFR4. PTEN loss and alteration of PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 and/or FGFR4.